Skip to main content
An official website of the United States government

Prostate and Urologic Cancers

Conducts and supports research on the prevention and early detection of prostate and bladder cancers. Develops and supports prevention trials and evaluation of new agents, surrogate biomarkers, and emerging technologies for identifying premalignant lesions.

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

Major Programs

Staff List

Photo Name, Email, Phone Room Group(s)/Office
Asefa, Mela
mela.asefa@nih.gov
240-276-6422
5E328 Program Support Assistant | Breast and Gynecologic Cancer
Program Support Assistant | Prostate and Urologic Cancer
House, Margaret, RN, B.S.N.
margaret.house@nih.gov
240-276-7047
5E306 Deputy Chief | Prostate and Urologic Cancer
Parnes, Howard L., M.D.
howard.parnes@nih.gov
240-276-7045
5E302 Chief | Prostate and Urologic Cancer

Grants

PI Name Sort descending PI Organization Title Grant Number Program Official
Herman, James G.

University Of Pittsburgh At Pittsburgh
United States

Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignancies 5U2CCA271885-04 Wendy Wang, Ph.D., M.Sc.
Herrmann, Joerg

Mayo Clinic Rochester
United States

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial 5R01CA233610-06 Eileen Dimond, R.N., M.S.
Hilakivi-Clarke, Leena A.

University Of Minnesota
United States

Effect of maternal obesity on breast cancer among offspring: role of the gut microbiota 5R01CA276775-03 Amit Kumar, Ph.D.
Hill, Joshua Aiden

Fred Hutchinson Cancer Center
United States

Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy 5R01CA276040-03 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Hitchins, Megan P

H. Lee Moffitt Cancer Ctr & Res Inst
United States

Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age 7R01CA252042-05 Matthew Young, Ph.D.
Hollingsworth, Michael A.

University Of Nebraska Medical Center
United States

Pancreatic Cancer Detection Consortium 5U01CA210240-09 Matthew Young, Ph.D.
Hoshida, Yujin

Ut Southwestern Medical Center
United States

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis 4U01CA288375-03 Sidney Fu, M.D.
Howitt, Brooke E

Stanford University
United States

Unraveling heterogeneity in endometrial cancer via integrated single cell genotype-phenotype mapping 1R37CA303960-01 Goli Samimi, Ph.D., M.P.H.
Hruska, Carrie B

Mayo Clinic Rochester
United States

Density MATTERS Clinical Trial 5R01CA239200-05 Claire Zhu, Ph.D.
Hsu, Li

Fred Hutchinson Cancer Center
United States

Statistical Methods for Precision Prevention 1R01CA297681-01 Claire Zhu, Ph.D.
Hu, Shuiying

Ohio State University
United States

Targeting neuronal transport to ameliorate vincristine neurotoxicity 5R01CA272254-03 Rachel Altshuler, Ph.D.
Hu, Jim

Weill Medical Coll Of Cornell Univ
United States

Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL) 5R01CA259173-04 Marjorie Perloff, M.D.
Huang, Ying

Fred Hutchinson Cancer Center
United States

Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies 5R01CA277133-03 Matthew Young, Ph.D.
Huang, Ying

Western University Of Health Sciences
United States

Preventing UV-induced immunosuppression and skin carcinogenesis with R-carvedilol 5R01CA269653-04 Anda Vlad, M.D., Ph.D.
Huang, Yijian

Emory University
United States

Analytic diagnosis methods for disease ruling 5R01CA283687-02 Guillermo Marquez, Ph.D.